Fig. 3From: Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AMLAnalysis of treatment sensitivity to quizartinib and chemotherapy. (a, b) Response to in vitro cytarabine treatment of total bone marrow. CFU number after treatment (a). Normalized CFU reduction (b). (mean ± SD. n = 3) 2-way ANOVA with Bonferroni multiple comparison was used for p values. c Scheme of in vivo treatment. d Histology of the bone marrow of AC220- and chemotherapy-treated groups. Scale bar, 100 μm. (e–h) Normalized CFU number reduction (e), normalized bone marrow LSK reduction (f), normalized bone marrow LK reduction (g), normalized bone marrow Gr-1−/CD11b+ reduction (h) (median ± IR. n = 6 to 10). Mann-Whitney test was used for p values. *p < 0.05, **p < 0.01, ***p < 0.001Back to article page